Table 1

Patient characteristics at baseline

TN ≥65 years (n = 31)R/R (n = 101)All patients (N = 132)
Median age, years (range)71 (65-84)64 (37-82)68 (37-84)
 ≥70 y, n (%)23 (74)34 (34)57 (43)
Sex, n (%)
 Male19 (61)79 (78)98 (74)
 Female12 (39)22 (22)34 (26)
ECOG PS, n (%)
 023 (74)43 (43)66 (50)
 18 (26)54 (53)62 (47)
 20 (0)4 (4)4 (3)
Bulky disease, n (%)
 ≥5 cm6 (19)55 (54)61 (46)
 ≥10 cm015 (15)15 (11)
Baseline Rai stage, n (%)
 0-II13 (42)38 (38)51 (39)
 III-IV17 (55)58 (57)75 (57)
 Unknown1 (3)5 (5)6 (5)
Cytogenetics/FISH, n (%)
 Del(17p)2 (6)34 (34)36 (27)
 Del(11q)1 (3)35 (35)36 (27)
 Trisomy 128 (26)12 (12)20 (15)
 Del(13q)17 (55)47 (47)64 (49)
 β2-microglobulin level >3 mg/L, n (%)8 (26)49 (49)57 (43)
 Unmutated IGHV, n (%)15 (48)79 (78)94 (71)
Median ANC, × 109/L (range)3.9 (0-19.4)2.5 (0-19)2.6 (0-19.4)
 ANC ≤1.5 × 109/L1 (3)34 (34)35 (27)
Median hemoglobin, g/L (range)122 (77-157)115 (62-176)117 (62-176)
 ≤11 g/dL, n (%)11 (35)42 (42)53 (40)
Median platelets, × 109/L (range)113 (32-217)105 (2-310)105 (2-310)
 ≤100 × 109/L, n (%)12 (39)49 (49)61 (46)
Hemoglobin ≤11 g/dL or platelets ≤100 × 109/L, n (%)20 (65)61 (60)81 (61)
Median ALC, × 109/L (range)41.1 (0.3-240.2)8.9 (0.1-298.9)13 (0.1-299)
Median CrCl, mL/min (range)67 (31-156)81 (36-213)79 (31-213)
 <60 mL/min, n (%)9 (29)20 (20)29 (22)
Median prior therapy, n (range)4 (1-12)
Number of prior therapies, n (%)
 1-227 (27)
 314 (14)
 ≥460 (59)
Prior systemic therapy, n (%)
 Chemotherapy101 (100)
 Nucleoside analog97 (96)
 Alkylator (including bendamustine)92 (91)
 Any anti-CD20–based therapy99 (98)
 Anti-CD20–based chemoimmunotherapy97 (96)
 Anti-CD52–based therapy (alemtuzumab)23 (23)
 Idelalisib6 (6)
  • CrCl, creatinine clearance; FISH, fluorescence in situ hybridization.